Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.34 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.32 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.31 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.30 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.30 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.30 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4686457 | 0.87 | CDK2 (0.39) | ALDH1A1PIK3CDCDK2 | |
| SCHEMBL21856180 | 0.84 | ALDH1A1 (0.42) | ALDH1A1CRHBPCRHR2PIK3CDNPC1 | |
| SCHEMBL29506013 | 0.84 | ALDH1A1 (0.42) | ALDH1A1CRHBPCRHR2PIK3CDNPC1 | |
| SCHEMBL15472996 | 0.83 | ALDH1A1 (0.47) | ALDH1A1RAB9AKDM4E | |
| SCHEMBL21727979 | 0.83 | ALDH1A1 (0.38) | ALDH1A1CRHBPCRHR2PIK3CDPIK3CA | |
| SCHEMBL14901108 | 0.83 | MAPK1 (0.36) | ALDH1A1CRHBPCRHR2PIK3CD | |
| SCHEMBL3638928 | 0.83 | PIK3CD (0.42) | ALDH1A1CRHBPCRHR2PIK3CDPIK3CA | |
| SCHEMBL16125086 | 0.83 | ALDH1A1 (0.38) | ALDH1A1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL14901137 | 0.82 | RPS6KA5 (0.34) | ALDH1A1CRHBPCRHR2RPS6KA5RPS6KA4 | |
| SCHEMBL20374464 | 0.78 | ALDH1A1 (0.41) | ALDH1A1PIK3CDPIK3CAMAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025149622-A1 | WNK1 INHIBITORS | DANIA THERAPEUTICS APS (DK) | 2025-07-17 | — | — | WO | disclosed |
| WO-2024057013-A1 | NLRP3 MODULATORS | EXSCIENTIA AI LIMITED (GB) | 2024-03-21 | — | — | WO | disclosed |
| EP-2776435-B1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LTD (GB) | 2018-06-27 | — | — | EP | disclosed |
| EP-2776435-B1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LTD (GB) | 2018-06-27 | — | — | EP | disclosed |
| US-10004733-B2 | — | — | 2018-06-26 | — | — | US | disclosed |
| US-10004733-B2 | — | — | 2018-06-26 | — | — | US | disclosed |
| US-10004733-B2 | — | — | 2018-06-26 | — | — | US | disclosed |
| US-9682141-B2 | Combination of kinase inhibitors and uses thereof | INTELLIKINE LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682141-B2 | Combination of kinase inhibitors and uses thereof | INTELLIKINE LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160235758-A1 | COMBINATION OF MTOR INHIBITORS AND PI3-KINASE INHIBITORS, AND USES THEREOF | INTELLIKINE LLC | 2016-08-18 | — | — | US | disclosed |
| WO-2013078441-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-05-30 | — | — | WO | disclosed |
| WO-2013071264-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-05-16 | — | — | WO | disclosed |
| WO-2013061080-A1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
| WO-2013061080-A1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
| EP-2575462-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Intellikine, LLC (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2012148540-A1 | COMBINATION OF KANASE INHIBITORS AND USES THREOF | INTELLIKINE, LLC (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2011149937-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011149937-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10004733-B2 | — | SDHB, SDHA, NDUFS5 | ALDH1A1 205/4885CRHBP 4372/4885CRHR2 4062/4885 |
| US-20160235758-A1 | COMBINATION OF MTOR INHIBITORS AND PI3-KINASE INHIBITORS, AND USES THEREOF | MTOR, RPTOR, RICTOR | ALDH1A1 4784/4885CRHBP 2288/4885CRHR2 1804/4885 |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | MTOR, AKT2, MTMR1 | ALDH1A1 4563/4885CRHBP 2485/4885CRHR2 1950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.